Therapeutic management of acute pulmonary embolism

References

• Sogaard KK, Schmidt M, Pedersen L, et al. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 2014;130(10):829–836.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033-69k.
   PubMed Web of Science ®Google Scholar
• Laporte S, Mismetti P, Decousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation. 2008;117(13):1711–1716.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041–1046.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet (London, England). 2011;378(9785):41–48.
   PubMed Web of Science ®Google Scholar
• Jimenez D, Lobo JL, Barrios D, et al. Risk stratification of patients with acute symptomatic pulmonary embolism. Intern Emerg Med. 2016;11(1):11–18.
   PubMed Web of Science ®Google Scholar
• Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383–1389.
   PubMedGoogle Scholar
• Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–1411.
   PubMed Web of Science ®Google Scholar
• Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia study. JTH. 2011;9(8):1500–1507.
   Google Scholar
• Weeda ER, Kohn CG, Peacock WF, et al. External validation of the Hestia criteria for identifying acute pulmonary embolism patients at low risk of early mortality. Clin Appl Thromb Hemost. 2016;107602961665114.
   Google Scholar
• den Exter PL, Zondag W, Klok FA, et al. Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without n-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism. A randomized clinical trial. Am J Respir Crit Care Med. 2016;194(8):998–1006.
   PubMed Web of Science ®Google Scholar
• Hellenkamp K, Kaeberich A, Schwung J, et al. Risk stratification of normotensive pulmonary embolism based on the sPESI - does it work for all patients? Int J Cardiol. 2015;197:162–163.
   PubMed Web of Science ®Google Scholar
• Zondag W, Vingerhoets LM, Durian MF, et al. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. JTH. 2013;11(4):686–692.
   Google Scholar
• van der Hulle T, Dronkers CE, Klok FA, et al. Recent developments in the diagnosis and treatment of pulmonary embolism. J Intern Med. 2016;279(1):16–29.
   PubMed Web of Science ®Google Scholar
• Vinson DR, Ballard DW, Mark DG, et al. Risk stratifying emergency department patients with acute pulmonary embolism: does the simplified pulmonary embolism severity index perform as well as the original? Thromb Res. 2016;148:1–8.
   PubMed Web of Science ®Google Scholar
• Klok FA, Meyer G, Konstantinides S. Management of intermediate-risk pulmonary embolism: uncertainties and challenges. Eur J Haematol. 2015;95(6):489–497.
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578–589.
   PubMed Web of Science ®Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104(1):49–60.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
   PubMed Web of Science ®Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–772.
   PubMed Web of Science ®Google Scholar
• van der Hulle T, Kooiman J, den Exter PL, et al., Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. JTH. 2014;12(3):320–328. •• These meta-analysis including five phase-3 trials comparing DOACs with VKAs in patients with acute VTE shows that DOACs and VKAs have a similar efficacy in the treatment of acute PE but a significant better safety profile.
   Google Scholar
• Dentali F, Di Minno MN, Gianni M, et al. Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Intern Emerg Med. 2015;10(4):507–514.
   PubMed Web of Science ®Google Scholar
• Brekelmans MP, Ageno W, Beenen LF, et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016;3(9):e437–45.
   PubMed Web of Science ®Google Scholar
• Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143–1150.
   PubMed Web of Science ®Google Scholar
• Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. JTH. 2014;12(4):459–468.
   Google Scholar
• Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414–2421.
   PubMed Web of Science ®Google Scholar
• Wang TF, Squizzato A, Dentali F, et al. The role of thrombolytic therapy in pulmonary embolism. Blood. 2015;125(14):2191–2199.
   PubMed Web of Science ®Google Scholar
• Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–1830.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S.
   PubMed Web of Science ®Google Scholar
• Meneveau N, Seronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129(4):1043–1050.
   PubMed Web of Science ®Google Scholar
• Wan S, Quinlan DJ, Agnelli G, et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110(6):744–749.
   PubMed Web of Science ®Google Scholar
• Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111(5):1241–1245.
   PubMed Web of Science ®Google Scholar
• Levine MN. Thrombolytic therapy for venous thromboembolism. Complications and contraindications. Clin Chest Med. 1995;16(2):321–328.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Weinberg I, Yeh RW, et al. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy development of the PE-CH Score. Thromb Haemost. 2016;117:246–251.
   PubMed Web of Science ®Google Scholar
• Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol. 2013;111(2):273–277.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254–262.
   PubMed Web of Science ®Google Scholar
• Hartman AR, Manetta F, Lessen R, et al. Acute surgical pulmonary embolectomy: a 9-year retrospective analysis. Tex Heart Inst J. 2015;42(1):25–29.
   PubMed Web of Science ®Google Scholar
• Kalra R, Bajaj NS, Arora P, et al. Surgical embolectomy for acute pulmonary embolism: systematic review and comprehensive meta-analyses. Ann Thorac Surg. 2017;103(3):982–990.
   PubMed Web of Science ®Google Scholar
• Bloomer T, Fong P, McDaniel M, et al. TCT-781 safety and outcomes of catheter-directed thrombolytic therapy in high-risk pulmonary embolism. J Am Coll Cardiol. 2016;68(18):B315–B316.
   Web of Science ®Google Scholar